Blocking FOXO4, which inhibits the activation of P53, causes senescent cells to undergo apoptosis by P53 activation, without affecting healthy cells around them, and has anti-aging effects which may have potential applications in the treatment of numerous age-related diseases, as well as an adjunct to treatment for certain forms of cancer
Perhaps most notably, only 2% of flexible patients stopped taking the drug by the studys end, compared to 19% of standard users
Rakipovski G, Rolin B, Nohr J, Klewe I, Frederiksen KS, Augustin R, et al
La D-carnitina no se encuentra de forma natural en los seres humanos